Innate Pharma completes enrollment in Phase 1 study of Nectin-4 ADC IPH4502

Innate Pharma announced on July 21, 2026 that it had completed enrollment in the dose escalation of the Phase 1 study of IPH4502, its proprietary Nectin-4 exatecan antibody-drug conjugate, with preliminary data readout from 76 patients expected by year-end.¹

The trial, known as IPH4502-101 (NCT06781983), is testing the drug's safety, tolerability, and early signs of anti-tumor activity in patients with advanced solid tumors that express Nectin-4, a group that includes urothelial carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and several other cancer types, according to the company. The dose-escalation portion enrolled 76 patients across sites in France and the United States.¹

On safety, the company reported that IPH4502 has shown limited hematological toxicity so far, which the company said may reflect slower release of free exatecan tied to its proprietary linker design.¹ On efficacy, the company reported early anti-tumor activity in heavily pretreated patients, including objective responses in urothelial carcinoma after prior treatment with enfortumab vedotin, as well as in non-small cell lung cancer and head and neck squamous cell carcinoma.¹

Innate describes IPH4502 as built on three components: exatecan, a topoisomerase I inhibitor, as the payload, which the company said may address some resistance issues seen with MMAE-based ADCs without requiring CYP2D6 genotyping¹; a proprietary stable linker meant to slow the release of free exatecan into circulation¹; and a proprietary humanized anti-Nectin-4 antibody that binds a different epitope than enfortumab vedotin.¹

Sonia Quaratino, the company's Chief Medical Officer, said the company is looking forward to the dose-escalation dataset by year-end, which will guide the path into dose optimization and further define the clinical potential of IPH4502.¹